Mythic Therapeutics
Mythic Therapeutics Logo

Mythic Therapeutics

Building smarter and safer antibody-drug conjugates.





Waltham, Massachusetts



Company Description

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Quick Links



Total Raised

$126.6 million



Significant Investors

First Round Capital, Viking Global Investors, Venrock, OMX Ventures, Lifeforce Capital, Refactor Capital

Company Traction

  • In April 2023, Mythic Therapeutics announced the first patient had been dosed in the Phase 1 KisMET-01 clinical trial of MYTX-011.

Leadership Team

  • Brian Fiske: Co-Founder & Chief Scientific Officer at Mythic Therapeutics. Former CTO at Ohana Biosciences.
  • Sandra Poole: COO at Mythic Therapeutics. Former COO at LogicBio Therapeutics.
  • Gilles Gallant, BPharm PhD FOPQ: Chief Development Officer at Mythic Therapeutics. Former SVP, Global Head, Oncology Clinical Development at Daiichi Sankyo.
  • Thomas Chittenden: SVP, Head of Biology at Mythic Therapeutics. Former Executive Director, Pipeline Research & Development at ImmunoGen.
  • Nimish Gera: VP of Biologics at Mythic Therapeutics. Former Research Scientist II, Discovery Research at Alexion Pharmaceuticals.


People also viewed